Competitive Intelligence Report on Sodium-Dependent Glucose (Co)Transporter (SGLT) Inhibitors Provides a Competitor Analysis for Treatment of Type 2 Diabetes.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/f88722/competitor_analysi) has announced the addition of the "Competitor Analysis Competitor analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. Created by Michael Porter competitor analysis focuses on four key aspects: competitor's objectives, competitor's assumptions, : Sodium-Dependent Glucose (Co-) Transporter (SGLT SGLT Sodium-Glucose Linked Transporter SGLT Space-Ground Link Terminal ) Inhibitors" report to their offering. This Competitive Intelligence report on Sodium-Dependent Glucose (Co)Transporter (SGLT) Inhibitors as of November 2008 provides a competitor analysis in the development pipeline of novel SGLT inhibitors for treatment of type 2 diabetes type 2 diabetes n. See diabetes mellitus. . Sodium-dependent glucose (co)transporters (SGLT are specifically expressed in the intestines Intestines The intestines, also known as the bowels, are divided into the large and small intestines. They extend from the stomach to the anus. Mentioned in: Malabsorption Syndrome (SGLT-1) and kidneys (SGLT-1). Inhibitors of SGLT-1 suppress absorption of glucose from the gut, while SGLT-2 inhibitors block the reabsorptoin of glucose from the renal filtrate filtrate /fil·trate/ (fil´trat) a liquid or gas that has passed through a filter. fil·trate v. To put or go through a filter. n. . Thus, SGLT inhibitors might be complementary approaches to traditional antidiabetics intervening with glucose metabolism glucose metabolism, n the process by which simple sugars found in many foods are processed and used to produce energy in the form of ATP. Once consumed, glucose is absorbed by the intestines and into the blood. . Most of the currently developed SGLT inhibitors are selective for SGLT-2, a minority is directed at SGLT-1 or SGLT-1/2. Although the most advanced SGLT-inhibitor now is in phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA clinical development, a high clinical stage drop-out rate characterizes the research and development efforts of novel SGLT inhibitors. At least ten SGLT inhibitors are in clinical development, predominantly by bigger pharmaceutical companies and many originating from Japan. Key Topics Covered: The report provides a compilation of current active and discontinued projects in research and development of novel SGLT-2, SGLT-1 and SGLT-1/2 inhibitors. Competitor projects are listed in a tabular format providing information on: -- Drug Codes, -- Target/Mechanism of Action, -- Class of Compound, -- Company, -- Product Category, -- Indication, -- R&D Stage, and -- additional comments with a hyperlink leading to the source of information. Index: -- SGLT-2 Inhibitors -- SGLT-1 and SGLT-1/2 Inhibitors -- Corporate SGLT Inhibitor R&D Pipelines -- About La Merie For more information visit http://www.researchandmarkets.com/research/f88722/competitor_analysi. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion